On June 9th, 2022, a phase 1/2 clinical trial (ALKOVE-1; NCT05384626) is ongoing and includes patients with solid tumors harboring ALK aberrations, including NSCLC, and patients are receiving NVL-655. The gene discussed is ALK; the disease is non-small cell lung carcinoma.